CYP2D6 and neoplasm: We stratified the patients by these factors and performed further analysis for CYP2D6. The association of CYP2D6 with favorable OS was seen only in patients with stage II tumour (Figure 2B) but not in any of the PAM50 subtypes (Figure S3B), or within the cohort (248 patients) treated with tamoxifen (Table S3).